Diagnosis of superficial esophageal cancer and dysplasia using endoscopic screening with a 2% lugol dye solution in patients with head and neck cancer

Citation
Aj. Tincani et al., Diagnosis of superficial esophageal cancer and dysplasia using endoscopic screening with a 2% lugol dye solution in patients with head and neck cancer, HEAD NECK, 22(2), 2000, pp. 170-174
Citations number
23
Categorie Soggetti
Otolaryngology
Journal title
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
ISSN journal
10433074 → ACNP
Volume
22
Issue
2
Year of publication
2000
Pages
170 - 174
Database
ISI
SICI code
1043-3074(200003)22:2<170:DOSECA>2.0.ZU;2-#
Abstract
Background. Head and neck cancer (HNC) has a high incidence in Brazil, with cancer of the oral cavity being one of the five most common cancers among Brazilians. Alcohol and tobacco consumption may contribute to synchronous o r metachronous HNC and esophageal cancer. The early detection of superficia l esophageal cancer and dysplasia in asymptomatic patients with HNC, after successfully treating the primary cancer. may provide an effective cure. Methods. A prospective study involving 60 patients with HNC was carried out at the State University of Campinas (UNICAMP) to screen for superficial es ophageal cancer and dysplasia using endoscopy and a 2% lugol dye solution f ollowed by biopsy of the suspicious areas. Results. Five patients (8.3%) had superficial esophageal cancer, which was diagnosed as intraepithelial carcinoma in three of them (5.0%). In four pat ients, the superficial esophageal cancer was synchronous, and in one it was metachronous to HNC. Five patients (8.3%) had dysplasias in the esophageal epithelium (three were classified as mild and two as moderate). Conclusion. These results demonstrate the value of endoscopic screening of the esophagus using lugol dye in patients with HNC, particularly because su perficial esophageal cancer is extremely difficult to detect by conventiona l methods in asymptomatic patients. (C) 2000 John Wiley & Sons, Inc.